Frankfurt
08.09.26 | 08:03
3,730 Euro
+1,08 % +0,040
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 3,685 | 3,830 | 19:46 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 18:23 | THX PHARMA: THX Pharma and the Beyond Batten Disease Foundation Announce the Grant of a European Patent Protecting the Use of Batten-1 in Juvenile Batten Disease (CLN3) | 296 | Actusnews Wire | A patent jointly owned by BBDF, Baylor College of Medicine and Cardiff University, and exclusively licensed worldwide to THX Pharma
Protection in Europe through July 2041, complementing THX... ► Artikel lesen | |
| 01.09. | THX PHARMA: THX Pharma, BBDF and Biocodex Announce Regulatory Submissions for the Phase 3 Clinical Trial of Batten-1 in Juvenile Batten Disease (CLN3) | 574 | Actusnews Wire | Lyon, France - Austin, Texas, USA - Gentilly, France - September 1, 2026 - 6:00 p.m. CEST - THX Pharma (Theranexus), an innovative biopharmaceutical company developing treatments for rare neurological... ► Artikel lesen | |
| 09.07. | THX PHARMA: THX Pharma Reports Cash Position as of June 30, 2026 | 597 | Actusnews Wire | Lyon, France - July 9, 2026 - 6:00 p.m. CET - THX Pharma (Theranexus), an innovative biopharmaceutical company focused on the treatment of rare neurological diseases, today announced its cash position... ► Artikel lesen | |
| 23.06. | THX PHARMA: THX Pharma Announces the Appointment of Sophie Jacq Lapointe to its Board of Directors | 486 | Actusnews Wire | A recognized leader in the pharmaceutical and biotechnology industry joins the Board of Directors to support THX Pharma's next phase of growth and development.
Lyon, France - June 23, 2026 - 6:00... ► Artikel lesen | |
| 16.06. | THX PHARMA: Allinvest Securities Initiates Analyst Coverage on THX Pharma with Buy Recommendation | 589 | Actusnews Wire | Lyon, France - June 16, 2026 - 8:00 AM CEST - THX Pharma (Theranexus), an innovative biopharmaceutical company specializing in the treatment of rare neurological diseases, today announces the initiation... ► Artikel lesen | |
| THX PHARMA Aktie jetzt für 0€ handeln | |||||
| 09.06. | Theranexus: THX Pharma, Biocodex and the Beyond Batten Disease Foundation Stand Together with the CLN3 Batten Community on International Batten Disease Awareness Day | 557 | ACCESS Newswire | The three partners are proud to jointly serve as Platinum Sponsors of the 2026 BDSRA Annual Family Conference, where they will provide an update on the Batten-1 program and the upcoming initiation of... ► Artikel lesen | |
| 09.06. | THERANEXUS: THX Pharma (Theranexus) and Exeltis secure EMA approval of the paediatric investigation plan (PIP) for TX01, unlocking the PUMA registration pathway | 789 | Actusnews Wire | Approval of the PIP by the EMA's Paediatric Committee (PDCO) clears a critical regulatory gate, paving the way for a Paediatric Use Marketing Authorisation (PUMA) submission and securing up to... ► Artikel lesen | |
| 09.06. | THERANEXUS: THX Pharma, Biocodex and the Beyond Batten Disease Foundation Stand Together with the CLN3 Batten Community on International Batten Disease Awareness Day | 1.604 | Actusnews Wire | The three partners are proud to jointly serve as Platinum Sponsors of the 2026 BDSRA Annual Family Conference, where they will provide an update on the Batten-1 program and the upcoming initiation... ► Artikel lesen | |
| 28.04. | THERANEXUS: THX Pharma Publishes Its 2025 Annual Results, Cash Position as of March 31, 2026, and Provides a Business Update | 960 | Actusnews Wire | Lyon, France - April 28, 2026 - 7:00 p.m. CEST - THX Pharma (Theranexus), an innovative biopharmaceutical company specializing in the treatment of rare neurological diseases, today announces its... ► Artikel lesen | |
| 25.03. | THERANEXUS: THX Pharma Announces the Publication of its Letter to Shareholders | 623 | Actusnews Wire | Lyon, France - March 25, 2026, 6:30 pm CET - THX Pharma (Theranexus), an innovative biopharmaceutical company in the treatment of rare neurological diseases, today announces the publication of... ► Artikel lesen | |
| 19.02. | THERANEXUS: THX Pharma Reports Its Cash Position as of December 31, 2025 | 723 | Actusnews Wire | Lyon, France - February 19, 2026, 6:00 p.m. CET - THX Pharma (Theranexus), an innovative biopharmaceutical company specializing in the treatment of rare neurological diseases, today announces... ► Artikel lesen | |
| 12.02. | THERANEXUS: THX Pharma to Host a Webinar to Discuss Its Strategic Agreement with Biocodex | 801 | Actusnews Wire | THX Pharma to Host a Webinar to Discuss Its Strategic Agreement with Biocodex
Lyon, France - February 12, 2026 - 6:00 p.m. CET - THX Pharma (Theranexus), an innovative biopharmaceutical company... ► Artikel lesen | |
| 10.02. | THX Pharma and Biocodex Announce a Strategic Licensing Agreement in Batten, Gaucher and Niemann-Pick Type C Diseases | 575 | Business Wire | THX Pharma (Theranexus) and Biocodex, an independent international pharmaceutical group, today announced the execution of a strategic licensing agreement to advance the development of two drug candidates... ► Artikel lesen | |
| 10.02. | THERANEXUS: THX Pharma and Biocodex announce a strategic licensing agreement covering three rare diseases | 979 | Actusnews Wire | Biocodex has acquired two licenses from THX Pharma to develop and commercialize Batten-1 worldwide and TX01 in the United States and Canada. The total deal value is up to €173 million, including... ► Artikel lesen | |
| 20.01. | THERANEXUS: THX Pharma Announces its 2026 Financial Calendar | 599 | Actusnews Wire | Lyon, France - January 20, 2026, 18:00 p.m. CET - THX Pharma (Theranexus), an innovative biopharmaceutical company in the treatment of rare neurological diseases, today announces its financial... ► Artikel lesen | |
| 08.01. | THERANEXUS: THX Pharma announces the publication of its letter to shareholders | 656 | Actusnews Wire | Lyon, France - January 8, 2025, 6:00 PM CET - THX Pharma (Theranexus), an innovative biopharmaceutical company in the treatment of rare neurological diseases, today announces the publication of... ► Artikel lesen | |
| 07.01. | THERANEXUS: THX Pharma Announces the Appointment of Julien Veys as Deputy Chief Executive Officer | 650 | Actusnews Wire | Lyon, France - January 7, 2026, 8:00 a.m. CET - The Board of Directors of THX Pharma (Theranexus), a pharmaceutical company specializing in rare neurological diseases, today announces the appointment... ► Artikel lesen | |
| 13.11.25 | THERANEXUS: THX Pharma announces the strong success of its approximately EUR 8 million capital increase to support its continued development and strengthen its financial structure | 896 | Actusnews Wire | Capital increase of €7.8 million through the issuance of 4,356,804 new shares at a unit price of €1.80
The transaction received strong support from existing shareholders, whose demand on irreducible... ► Artikel lesen | |
| 27.10.25 | XFRA CAPITAL ADJUSTMENT INFORMATION - 27.10.2025 | 750 | Xetra Newsboard | Das Instrument XPGB NO0010736879 VEND MARKETPLAC. B NK-,50 EQUITY wird cum Kapitalmassnahme gehandelt am 27.10.2025 und ex Kapitalmassnahme am 28.10.2025 The instrument XPGB NO0010736879 VEND MARKETPLAC.... ► Artikel lesen | |
| 23.10.25 | THX Pharma announces the launch of a capital increase with preferential subscription rights of nearly EUR 8 million | 2.323 | Actusnews Wire | Subscription and guarantee commitments totaling €5.9 million, representing 75.5% of the envisaged capital increase
Subscription price: €1.80 per share, representing a 29.4% discount to the... ► Artikel lesen |
1 2 Weiter >>
24 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 85,50 | -4,04 % | BioNTech-Aktie: Diese Daten könnten die Wende bringen | Bei BioNTech geht es derzeit ordentlich hin und her. Erst sprang die Aktie nach positiven Krebsimpfstoff-Daten von Moderna kräftig nach oben, dann folgte mit dem Abbruch einer eigenen Darmkrebsstudie... ► Artikel lesen | |
| EVOTEC | 3,162 | -1,62 % | Kursexplosion wie bei Moderna? Übernahmekandidaten Evotec, Valneva und Vidac Pharma im Check! Analysten bullisch! | Moderna hat den Biotech-Markt mit dem Durchbruch bei der Bekämpfung von Hautkrebs wachgerüttelt. Partner Merck kommt in der Berichterstattung etwas zu kurz. Dabei bereitet sich der Pharmariese auf das... ► Artikel lesen | |
| BB BIOTECH | 57,40 | -0,35 % | BB Biotech Investmentprozess: KI verändert das Wie, nicht das Was | ||
| MEDIGENE | 0,005 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 30.06.2026 | The following instruments on Boerse Frankfurt do have their last trading day on 30.06.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 30.06.2026ISIN NameBE0003593044 COFINIMMOCA8765111064 TASEKO... ► Artikel lesen | |
| MODERNA | 123,24 | -0,40 % | How Is Moderna's Stock Performance Compared to Other Healthcare Stocks | ||
| VALNEVA | 2,900 | -0,89 % | Valnevas Wendepunkt: EMA-Antrag und Analysten-Euphorie erschüttern den Markt | ||
| EPIGENOMICS | 0,900 | -3,74 % | PTA-News: Epigenomics AG: Kapitalerhöhung in Höhe von EUR 219.244,00 vollständig gezeichnet | DJ PTA-News: Epigenomics AG: Kapitalerhöhung in Höhe von EUR 219.244,00 vollständig gezeichnet
Unternehmensmitteilung für den Kapitalmarkt
Epigenomics AG: Kapitalerhöhung in Höhe von EUR... ► Artikel lesen | |
| NOVAVAX | 8,880 | +2,07 % | Novavax-Aktie: Ist das im Zuge von Moderna die nächste Kursrakete? Die MRNA Krebs-Impfstoff-Welle hat begonnen! | © Foto: Tara Winstead auf PexelsBei Moderna ging es zuletzt steil nach oben, sehr spektakulär. Und jetzt könnte Novavax nachziehen. Der Grund bei Moderna ist ein Paukenschlag aus der Krebsforschung... ► Artikel lesen | |
| STRYKER | 240,10 | -7,58 % | Stryker introduces first of its kind FDA-authorized surgical application for Apple Vision Pro with hip arthroscopy case at nationally recognized academic medical center | SportSuite Vision brings spatial computing into the operating room, providing surgeons access to critical clinical information
Stryker announced the successful completion of the first... ► Artikel lesen | |
| BIOGEN | 183,20 | -3,85 % | Biogen Inc.: Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC) | -4-year data from the Phase 1/2a open-label extension (OLE) studies showed substantial and durable reductions in seizures and continuing improvements in cognition and behavior in patients treated with... ► Artikel lesen | |
| BIOFRONTERA | 2,370 | -4,44 % | PTA-Adhoc: Biofrontera AG: Biofrontera AG beschließt Vorbereitung des Wechsels vom regulierten Markt (Prime Standard) in das Börsensegment Scale | DJ PTA-Adhoc: Biofrontera AG: Biofrontera AG beschließt Vorbereitung des Wechsels vom regulierten Markt (Prime Standard) in das Börsensegment Scale
Veröffentlichung von Insiderinformationen gemäß... ► Artikel lesen | |
| ILLUMINA | 184,22 | -1,82 % | S&P Dow Jones Indices: Bloom Energy, Illumina, and Everpure Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400, and S&P SmallCap 600 | NEW YORK, Sept. 4, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P 100, S&P MidCap 400, and S&P SmallCap 600 indices... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 47,035 | -0,30 % | Where Will CRISPR Therapeutics Stock Be in 5 Years? | ||
| NANOREPRO | 1,745 | +1,45 % | EQS-News: NanoRepro AG: Strategische Neuordnung der Beteiligung hyped about science GmbH - vollständige Übernahme und Fokus auf Kerngeschäft sowie die Wachstumsträger PAEDIPROTECT, newkee, ZuhauseTEST und alpha | EQS-News: NanoRepro AG
/ Schlagwort(e): Beteiligung/Unternehmensbeteiligung/Beteiligung/Unternehmensbeteiligung
NanoRepro AG: Strategische Neuordnung der Beteiligung hyped about... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 696,00 | -1,63 % | Vertex vs. Regeneron: Which Biotech Giant Is the Better Buy Right Now? |
THX PHARMA SA gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +1,08 % bei einem Aktienkurs von 3,730 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu THX PHARMA SA finden Sie auf Wallstreet Online.